Clinical Trials
9 trialsNCT00788125 2023-07-14
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Phase 1/2 Terminated
NCT01261247 2022-05-24
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00598169 2020-08-10
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 1 Completed
NCT01682044 2017-10-09
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Roswell Park Cancer Institute
Phase 2 Completed
NCT01383447 2017-08-08
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01075425 2016-04-15
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
Phase 1 Completed
NCT01658319 2015-08-13
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01251250 2014-01-13
Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT01016990 2014-01-10
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown